Cargando…
Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration
BACKGROUND: Bisphosphonate (BP) is an effective drug for the prevention and treatment of osteoporosis. However, gastrointestinal distress caused by BP is a well-known side effect for low compliance. The aim of our study was to compare the 1-year persistence, compliance and T-scores between the aperi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Society for Bone and Mineral Research
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416146/ https://www.ncbi.nlm.nih.gov/pubmed/30899723 http://dx.doi.org/10.11005/jbm.2019.26.1.39 |
_version_ | 1783403292453240832 |
---|---|
author | Park, Chan Ho Jung, Ki Jin Nho, Jae-Hwi Kim, Ja-Hyung Won, Sung Hun Chun, Dong-Il Byun, Dong-Won |
author_facet | Park, Chan Ho Jung, Ki Jin Nho, Jae-Hwi Kim, Ja-Hyung Won, Sung Hun Chun, Dong-Il Byun, Dong-Won |
author_sort | Park, Chan Ho |
collection | PubMed |
description | BACKGROUND: Bisphosphonate (BP) is an effective drug for the prevention and treatment of osteoporosis. However, gastrointestinal distress caused by BP is a well-known side effect for low compliance. The aim of our study was to compare the 1-year persistence, compliance and T-scores between the aperitif medication group and the postprandial medication group. METHODS: Three hundred patients were included in this study to determine their persistence and compliance with the prescribed daily BP (Maxmarvil®, alendronate 5 mg and calcitriol 0.5 µg; YuYu Pharm) following distal radius fractures. Patients in Group 1 (aperitif medication) were asked to adhere to the general guidelines for BPs before breakfast. Patients in Group 2 (postprandial medication) were recommended medication after breakfast. We compared the persistence and compliance of this daily BP therapy using the medication possession ratio (MPR) and T-scores between the 2 groups after 1 year. RESULTS: Bone mineral density in hip and lumbar spine was improved significantly in 2 groups (P<0.001). Significant differences existed between 2 groups, including 73 of 150 patients (48.7%) in Group 1, and 111 of 150 patients (73.3%) in Group 2 for 1-year persistence (P=0.001). The mean MPR is 0.66 in Group 1 (range, 0.50–0.86) and 0.71 in Group 2 (range, 0.54–0.87). A significant difference was detected between the 2 groups (P=0.002). CONCLUSIONS: Postprandial administration improved persistence and compliance with daily BP therapy, resulting in better clinical outcomes. |
format | Online Article Text |
id | pubmed-6416146 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | The Korean Society for Bone and Mineral Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-64161462019-03-21 Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration Park, Chan Ho Jung, Ki Jin Nho, Jae-Hwi Kim, Ja-Hyung Won, Sung Hun Chun, Dong-Il Byun, Dong-Won J Bone Metab Original Article BACKGROUND: Bisphosphonate (BP) is an effective drug for the prevention and treatment of osteoporosis. However, gastrointestinal distress caused by BP is a well-known side effect for low compliance. The aim of our study was to compare the 1-year persistence, compliance and T-scores between the aperitif medication group and the postprandial medication group. METHODS: Three hundred patients were included in this study to determine their persistence and compliance with the prescribed daily BP (Maxmarvil®, alendronate 5 mg and calcitriol 0.5 µg; YuYu Pharm) following distal radius fractures. Patients in Group 1 (aperitif medication) were asked to adhere to the general guidelines for BPs before breakfast. Patients in Group 2 (postprandial medication) were recommended medication after breakfast. We compared the persistence and compliance of this daily BP therapy using the medication possession ratio (MPR) and T-scores between the 2 groups after 1 year. RESULTS: Bone mineral density in hip and lumbar spine was improved significantly in 2 groups (P<0.001). Significant differences existed between 2 groups, including 73 of 150 patients (48.7%) in Group 1, and 111 of 150 patients (73.3%) in Group 2 for 1-year persistence (P=0.001). The mean MPR is 0.66 in Group 1 (range, 0.50–0.86) and 0.71 in Group 2 (range, 0.54–0.87). A significant difference was detected between the 2 groups (P=0.002). CONCLUSIONS: Postprandial administration improved persistence and compliance with daily BP therapy, resulting in better clinical outcomes. The Korean Society for Bone and Mineral Research 2019-02 2019-02-28 /pmc/articles/PMC6416146/ /pubmed/30899723 http://dx.doi.org/10.11005/jbm.2019.26.1.39 Text en Copyright © 2019 The Korean Society for Bone and Mineral Research http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Park, Chan Ho Jung, Ki Jin Nho, Jae-Hwi Kim, Ja-Hyung Won, Sung Hun Chun, Dong-Il Byun, Dong-Won Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration |
title | Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration |
title_full | Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration |
title_fullStr | Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration |
title_full_unstemmed | Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration |
title_short | Impact on Bisphosphonate Persistence and Compliance: Daily Postprandial Administration |
title_sort | impact on bisphosphonate persistence and compliance: daily postprandial administration |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416146/ https://www.ncbi.nlm.nih.gov/pubmed/30899723 http://dx.doi.org/10.11005/jbm.2019.26.1.39 |
work_keys_str_mv | AT parkchanho impactonbisphosphonatepersistenceandcompliancedailypostprandialadministration AT jungkijin impactonbisphosphonatepersistenceandcompliancedailypostprandialadministration AT nhojaehwi impactonbisphosphonatepersistenceandcompliancedailypostprandialadministration AT kimjahyung impactonbisphosphonatepersistenceandcompliancedailypostprandialadministration AT wonsunghun impactonbisphosphonatepersistenceandcompliancedailypostprandialadministration AT chundongil impactonbisphosphonatepersistenceandcompliancedailypostprandialadministration AT byundongwon impactonbisphosphonatepersistenceandcompliancedailypostprandialadministration |